Buscar en
Actas Urológicas Españolas (English Edition)
Toda la web
Inicio Actas Urológicas Españolas (English Edition) Advances in uro-oncology “OncoForum”: The best of 2010
Journal Information
Vol. 35. Issue 6.
Pages 315-324 (June 2011)
Share
Share
Download PDF
More article options
ePub
Visits
1558
Vol. 35. Issue 6.
Pages 315-324 (June 2011)
Special article
Advances in uro-oncology “OncoForum”: The best of 2010
Avances en uro-oncología “OncoForum”: lo mejor del 2010
Visits
...
F. Gómez-Veigaa,??
Corresponding author
fgveiga@telefonica.net

Corresponding author.
, A. Alcaraz-Asensiob, J. Burgos-Revillac, J.M. Cózar-Olmod
a Servicio de Urología, Complejo Hospitalario Universitario de A Coruña, La Coruña, Spain
b Servicio de Urología, Hospital Clinic, Barcelona, Spain
c Servicio de Urología, Hospital Ramón y Cajal, Madrid, Spain
d Servicio de Urología, Hospital Virgen de la Nieves, Granada, Spain
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (3)
Show moreShow less
Tables (5)
Table 1. Results at 10 years of EORTC 22911.a
Table 2. The risk of overall deterioration of renal function or of achieving a glomerular filtration rate <60ml/min is similar in patients with ileal conduit and ileal orthotopic neobladder.20
Table 3. Several predictors of occult multifocality were identified in patients undergoing radical nephrectomy for clinically localized renal cell carcinoma (n=560; logistic regression analysis).29,30
Table 4. The toxicity of the combination temsirolimus-bevacizumab was higher and the progression-free rate at 48 weeks was lower compared with the sunitinib or the combination of bevacizumub and interferon-α.31
Table 5. Neoadjuvant chemotherapy to lymphadenectomy with paclitaxel, ifosfamide and cisplatin can induce clinically meaningful responses and may improve overall survival, according to a study carried out in 30 patients with N2-3 squamous cell penile cancer.40
Show moreShow less
Abstract
Objective

To highlight the most important issues of the 2010 annual meetings of the European Association of Urology (EAU), the American Urological Association (AUA), the American Society of Clinical Oncology (ASCO), and the American Society for Therapeutic Radiology and Oncology (ASTRO).

Methods

A group of experts in oncological urology selected the most important summaries of the four congresses. Subsequently, the revisers assessed the findings in relation to their present and future impacts on clinical practice. This document includes the summaries with the highest points.

Results

The following messages were considered important. In pT3 prostate cancer, postoperative radiotherapy (RT) improves local control and biochemical progression-free survival, with no significant impact on distant metastasis and overall survival. In patients with bladder cancer without muscle invasion and with the risk of intermediate recurrence, maintenance chemotherapy does not increase recurrence-free survival after transurethral resection. There is no evidence of a synergist effect of the combination of Temsirolimus/Bevacizumab in patients with metastatic kidney cell carcinoma without prior treatment. In the SWENOTECA V protocol for the treatment of seminomatous germ-cell testicular cancer, the adjuvant RT was interrupted because the concern regarding the induction of secondary cancers was greater than the reduction of relapses.

Conclusions

In 2010, new data were produced on the diagnosis and treatment in oncological urology, thanks to the interesting work of different trials.

Keywords:
Prostate neoplasias
Neoplasia of the urinary bladder
Kidney neoplasias
Testicular neoplasias
Penile neoplasias
Urology
Resumen
Objetivo

Destacar lo más relevante de las reuniones anuales 2010 de la Asociación Europea de Urología (European Association of Urology [EAU]), la Asociación Americana de Urología (American Urological Association [AUA]), la Sociedad Americana de Oncología Clínica (American Society of Clinical Oncology [ASCO]) y la Sociedad Americana de Oncología Radioterápica (American Society for Therapeutic Radiology and Oncology [ASTRO]).

Métodos

Un grupo de expertos en urología oncológica seleccionó los resúmenes más relevantes de los 4 congresos. Posteriormente, los revisores valoraron los hallazgos en relación con su impacto presente y futuro sobre la práctica clínica. Este documento recoge los resúmenes con mayor puntuación.

Resultados

Se han considerado relevantes los siguientes mensajes. En cáncer de próstata pT3 la radioterapia (RT) postoperatoria mejora el control local y supervivencia libre de progresión bioquímica, sin impacto significativo sobre las metástasis a distancia y la supervivencia global. En pacientes con cáncer vesical sin invasión muscular y con riesgo de recurrencia intermedio, la quimioterapia de mantenimiento no aumentó la supervivencia sin recurrencia después de resección transuretral. No hay evidencia de efecto sinergista de la combinación temsirolimus/bevacizumab para pacientes con carcinoma de células renales metastásico sin tratamiento previo. En el protocolo SWENOTECA V para el tratamiento del cáncer testicular de células germinales seminomatoso se interrumpió la RT adyuvante, porque la preocupación por la inducción de cánceres secundarios superaba a la reducción de las recidivas.

Conclusiones

En el 2010 han surgido nuevos datos sobre el diagnóstico y tratamiento en urología oncológica, gracias al interesante trabajo de diferentes estudios.

Palabras clave:
Neoplasias prostáticas
Neoplasias de la vejiga urinaria
Neoplasias renales
Neoplasias testiculares
Neoplasias del pene
Urología

Article

These are the options to access the full texts of the publication Actas Urológicas Españolas (English Edition)
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Actas Urológicas Españolas (English Edition)

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
Tools
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos